News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ChromaDex, Inc. Introduces New Caffeine Ingredient Technology, PURENERGY™



4/1/2013 9:41:30 AM

IRVINE, Calif., April 1, 2013 /PRNewswire/ -- ChromaDex Corporation® (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today the introduction of PURENERGY, a patented co-crystal ingredient comprised of caffeine and ChromaDex's pTeroPure® pterostilbene that forms a unique crystalline structure having significant advantages as compared to caffeine alone.

(Logo: http://photos.prnewswire.com/prnh/20110830/LA59283LOGO)

PURENERGY demonstrated in animal models a 6-8 times longer half-life as compared to caffeine alone.1 This suggests that PURENERGY may provide longer sustained energy and alertness with a more gradual finish, preventing the "crash" typically experienced when ingesting caffeinated products. This patented new ingredient technology should allow formulators of caffeinated products the opportunity to reduce the total amount of caffeine without affecting the consumers' product experience.

Frank Jaksch, co-founder and CEO of ChromaDex stated, "There has been and will continue to be tremendous demand for caffeinated products across many markets including energy, functional beverages, sports nutrition and weight loss. We believe that PURENERGY offers a responsible, next-generation alternative to heavy doses of caffeine. PURENERGY balances the consumer's desire to feel the effects of caffeine with the pressure consumer product companies are under to reduce caffeine levels in finished products."

Recently, highly caffeinated products have been coming under increased regulatory and political scrutiny regarding the possible risks of consuming high amounts caffeine. Specifically:

Given the co-crystal formulation of caffeine with pTeroPure, PURENERGY also has additional functional health benefits that include cognitive function, antioxidant activity, heart health and weight management support. ChromaDex's patented pTeroPure is a 99 percent pure, nature-identical pterostilbene with seven patents pending or issued. pTeroPure was named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan. PURENERGY and pTeroPure are manufactured exclusively for ChromaDex by Laurus Labs, one of the leaders in API manufacturing.

1 Data on file

About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model which utilizes its wholly-owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The Company provides seamless science-based solutions to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. Our ingredient technologies unit includes products backed with extensive scientific research and intellectual property. The ingredient portfolio includes pTeroPure® pterostilbene; ProC3G, a natural black rice containing cyanidine-3-glucoside; PURENERGY, a caffeine-pTeroPure co-crystal; nutraGac, a gac fruit powder; curcumin, and nicotinamide riboside, a novel next-generation B-vitamin currently under development. To learn more about ChromaDex please visit www.chromadex.com.

Forward-Looking Statements:

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Media Inquiries:
Chandler Chicco Agency
Amy Burkhalter, Media Specialist
310-309-1009
aburkhalter@ccapr.com

ChromaDex Investor Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
bprag@delmarconsulting.com

or

Alex Partners, LLC
Scott Wilfong, President
425-242-0891
Scott@alexpartnersllc.com

ChromaDex Contact:
Laura Carney, Executive Assistant
949-419-0288
laurac@chromadex.com

These statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

SOURCE ChromaDex Corporation


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES